DMRA
Damora Therapeutics, Inc.
NASDAQ: DMRA · HEALTHCARE · BIOTECHNOLOGY
$25.36
-1.17% today
Updated 2026-05-01
Market cap
$1.46B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.98
Dividend yield
—
52W range
$2 – $38
Volume
0.3M
Damora Therapeutics, Inc. (DMRA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | — | $111000.00 | $188000.00 | $441000.00 | $490000.00 | $830000.00 | $181000.00 | $34000.00 |
| Gross profit | — | $-111000.00 | $-188000.00 | $-441000.00 | $-490000.00 | $-830000.00 | $-181000.00 | $-34000.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $10.09M | $36.53M | $24.63M | $38.49M | $48.21M | $23.77M | $6.40M | $201.19M |
| SG&A | — | — | — | $13.74M | $13.00M | $12.69M | $10.50M | $9.69M |
| Operating income | $-12.91M | $-38.97M | $-33.64M | $-52.23M | $-61.21M | $-36.46M | $-16.90M | $-210.87M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-12.91M | $-38.86M | $-33.45M | $-51.79M | $-60.72M | $-35.63M | $-16.72M | $-210.84M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | — | $-38.97M | $-33.64M | $-52.23M | $-61.21M | $-36.46M | $-16.90M | $-210.87M |
| Interest expense | $2.97M | — | — | — | — | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-15.87M | $-36.51M | $-34.84M | $-51.75M | $-61.62M | $-38.35M | $-21.44M | $-209.84M |
| Net income growth (YoY) | — | -130.1% | +4.6% | -48.6% | -19.1% | +37.8% | +44.1% | -878.8% |
| Profit margin | — | — | — | — | — | — | — | — |